ALKBH5通过抑制CEMIP介导的EMT来调节NSCLC中帕克利塔塞尔耐药性的作用
Lingyue Gao1, Li Qiao1, Yingying Li1
1Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
Toxicology and applied pharmacology
|January 10, 2024
概括
N6-甲基氨酸 (m6A) 脱甲基酶ALKBH5作为非小细胞肺癌 (NSCLC) 的瘤抑制剂. ALKBH5针对CEMIP,影响NSCLC中的化疗耐药性和上皮-介质细胞过渡 (EMT).
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- N6-甲基氨酸 (m6A) 是一种关键的mRNA修饰,与癌症进展有关.
- 一种m6A脱甲基酶ALKBH5在癌症中经常失调,但其在非小细胞肺癌 (NSCLC) 化疗耐药性中的作用尚不清楚.
研究的目的:
- 调查ALKBH5在NSCLC病变发生和帕克利塔塞尔 (PTX) 耐药性的功能和机制.
- 阐明ALKBH5,上皮层-介质细胞过渡 (EMT) 和NSCLC中的化疗敏感性之间的关系.
主要方法:
- 对PTX抗性NSCLC细胞中ALKBH5表达的分析和患者的预后.
- 过度表达和淘汰实验,以评估ALKBH5对细胞增殖,化疗敏感性和EMT的影响.
- RNA测序,实时PCR和西部抹杀用于识别下游目标和阐明机制.
主要成果:
- ALKBH5表达在抗PTX的NSCLC细胞中减少,并与预后不佳有关.
- 在抗PTX细胞中,ALKBH5过度表达抑制了增殖,增强了化疗敏感性,并逆转了EMT.
- ALKBH5通过降低CEMIP mRNA稳定性来负面调节CEMIP,将CEMIP确定为下游目标.
结论:
- 在NSCLC中,ALKBH5/CEMIP轴在调节EMT中起着至关重要的作用.
- ALKBH5通过调节CEMIP稳定性和影响对PTX的化疗敏感性而起瘤抑制作用.
- 准ALKBH5/CEMIP通路可能为克服NSCLC中PTX抵抗提供治疗策略.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


